Balance Sheet

Cash Flow Statement

Acquisitions Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Beginning Cash Balance Beginning Cash Balance Capital Expenditures Capital Expenditures Cash from Discontinued Operations Cash from Discontinued Operations Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Net Loans Change in Receivables Change in Receivables Change in Taxes Change in Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Divestments Dividends Paid - Common Dividends Paid - Common Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other financing activities Other financing activities Preferred Shares Issued Preferred Shares Repurchased Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased Short-Term Debt issuances Short-Term Debt repayments

Daily Values

Growth Metrics

Fortress Biotech (FBIO) Amortization of Deferred Charges (2016 - 2023)

Fortress Biotech has reported Amortization of Deferred Charges over the past 9 years, most recently at $177000.0 for Q3 2023.

Quarterly results put Amortization of Deferred Charges at $177000.0 for Q3 2023, down 11.94% from a year ago — trailing twelve months through Jun 2024 was $177000.0 (down 66.48% YoY), and the annual figure for FY2023 was $353000.0, down 54.16%.
Amortization of Deferred Charges for Q3 2023 was $177000.0 at Fortress Biotech, up from $85000.0 in the prior quarter.
Over the last five years, Amortization of Deferred Charges for FBIO hit a ceiling of $221000.0 in Q1 2021 and a floor of $85000.0 in Q2 2023.
Median Amortization of Deferred Charges over the past 4 years was $177000.0 (2023), compared with a mean of $173400.0.
Biggest five-year swings in Amortization of Deferred Charges: skyrocketed 47.33% in 2021 and later tumbled 60.47% in 2023.
Fortress Biotech's Amortization of Deferred Charges stood at $205000.0 in 2020, then decreased by 19.51% to $165000.0 in 2021, then dropped by 8.48% to $151000.0 in 2022, then grew by 17.22% to $177000.0 in 2023.
The last three reported values for Amortization of Deferred Charges were $177000.0 (Q3 2023), $85000.0 (Q2 2023), and $91000.0 (Q1 2023) per Business Quant data.